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Background: Statherin is an important salivary protein for maintaining oral health. The purpose of the current
study was to determine if differences in statherin levels exist between diabetic and healthy subjects.
Methods:A total of 48 diabetic and healthy controls were randomly selected from a community-based database. Di-
abetic subjects (n=24) had fasting glucose levels N180mg/dL, while controls (n=24) had levels b110mg/dL. Pa-
rotid saliva (PS) and sublingual/submandibular saliva (SS) were collected and salivary ﬂow rates determined.
Salivary statherin levels were determined by densitometry of Western blots. Blood hemoglobin A1c (HbA1c) and
total protein in saliva were also obtained.
Results: SS, but not PS, salivary ﬂow rate and total protein in diabetics were signiﬁcantly less than those in healthy
controls (p = 0.021 & p b 0.001 respectively). Correlation analysis revealed the existence of a negative correlation
betweenPS statherin levels andHbA1c (p=0.012) and fasting glucose (p=0.021) levels,while no such correlation
was found for SS statherin levels. When statherin levels were normalized to total salivary protein, the proportion of
PS statherin, but not SS statherin, in diabeticswas signiﬁcantly less than that in controls (p=0.032). In contrast, the
amount of statherin secretion in SS, but not PS, was signiﬁcantly decreased in diabetics compared to controls (p =
0.016).
Conclusions and general signiﬁcance: The results show that synthesis and secretion of statherin is reduced in diabetics
and this reduction is salivary gland speciﬁc. As compromised salivary statherin secretion leads to increased oral
health risk, this study indicates that routine oral health assessment of these patients is warranted.Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes mellitus is a growing global epidemic with more than
439 million projected to be affected by 2030 [3]. Oral diseases, such as
periodontitis, dental caries, fungal infection, xerostomia, and salivary
gland dysfunction, are all major complications associated with diabetes
[6,17]. Saliva contains a number of components, such as electrolytes,n and Clinical Center (GRECC),
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ss article under the CC BY-NC-ND licmultiple buffering systems, digestive enzymes, lubricant glycoproteins,
and antimicrobial proteins, to maintain oral homeostasis and preserve
the health of the teeth and oral mucosa and prevent infection. There-
fore, salivary dysfunction may account for a number of the oral diseases
associated with diabetes and may be a risk factor for these patients. In-
deed, decreased salivary ﬂow rates have been documented in clinical
cohort studies and animal models of diabetes [17,23,31]. Further, a lim-
ited number of studies have reported changes in saliva composition,
such as amylase, total protein and antimicrobial proteins, in diabetic pa-
tients [6,14,23,27].
Human salivary statherin is a low molecular weight phosphoprotein,
containing 43 amino acids, that functions to inhibit spontaneous pre-
cipitation of calciumand phosphate salts (primary precipitation) from sa-
liva and the growth of hydroxyapatite crystals (secondary precipitation)
on the surface of the teeth [18,20]. In addition, statherin is amajor compo-
nent of the “acquired”dental pellicle and functions to regulatemineraliza-
tion at the surface through binding of its hydrophilic N-terminal domain
to hydroxyapatite and selection of oral microorganisms that bind to theense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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statherin inwhole saliva has been reported to be higher in caries-free pa-
tients than in caries-susceptible patients and those with elevated
decayed, missing, and ﬁlled teeth (DMFT) indices [29]. Based on these
observations, it is generally believed that statherin plays a critical role in
protecting oral tissues from a number of common dental disorders
(e.g., periodontal diseases, dental caries and oral mucosa infections) [11,
25].
Previous studies have shown that oral health in patients with type 2
diabetes is compromised and that many of the problems these patients
have are attributable to reduced salivary production or secretion and al-
terations in the composition of their saliva [17,23,31]. In other studies,
statherin expression in labial, submandibular, and parotid gland tissue,
obtained from control and diabetic (type 2) patients undergoing head
and neck tumor resection, was examined using immunogold labeling
and transmission electron microscopy (TEM). Statherin immunoreac-
tivity was detected in small vesicles, diffusely localized throughout the
cytoplasm of labial serous cells, and in secretory granules of serous
acinar cells in both submandibular and parotid glands [11–13]. Detailed
statistical analyses revealed that the number of stained particles was
signiﬁcantly lower in tissues of diabetic subjects than non-diabetic
controls. Recent proteome and peptidome analyses of saliva from chil-
dren with type 1 diabetes also suggest a relatively lower production of
statherin than those in controls [1].
Since the earlier studies, mentioned above, demonstrated decreased
production of statherin in salivary gland tissue (type 2 diabetics) and sa-
liva (type 1 diabetics), the current study aimed to determine whether
there are measurable differences in salivary statherin from sublingual/
submandibular and parotid glands from normal (n = 24) and type 2
diabetic (n=24)middle aged subjects. Changes in statherin production
were also evaluated for correlation with fasting blood glucose and
HbA1c levels andDMFT indices. The overall goal was to evaluatewheth-
er salivary statherin had potential as a marker of salivary dysfunction,
oral health, and overall disease activity in type 2 diabetes.
2. Materials and methods
2.1. Subjects
A total of 48 subjects, 24 diabetic and 24 healthy age- and gender-
matched controls, were randomly selected from 1322 subjects in the
OralHealth: SanAntonio Longitudinal Study of Aging (OH: SALSA) data-
base [6] which included both Mexican American and European
American ethnic groups. The number of subjects to be included in the
studywasestimatedusinga power analysis (effect size=0.85,αerror=
0.05, power = 0.80) and based on a preliminary study of PS. The study
protocol was approved by the Institutional Review Board of the Univer-
sity of TexasHealth Science Center at San Antonio and informed consent
was obtained from each participant. Diabetic subjects were identiﬁed
based on fasting plasma glucose levels N180 mg/dL. Control subjects
(non-diabetic), with comparable age and gender to the diabetic cohort,
were identiﬁed by having nomajor health problems and fasting plasma
glucose levels b110mg/dL. Some of the control subjects, however, were
taking anti-cholesterolemic or anti-hypertensive medications. Body
mass index (BMI), HbA1c, and oral health status were also obtained
for both groups, but not used as selection criteria.
2.2. Saliva collection
Parotid saliva (PS) and sublingual/submandibular saliva (SS) pro-
duction were stimulated and collected as previously described [6]. In
brief, PS was collected using a modiﬁed Carlson–Crittenden cup, while
SS was collected using a micropipette connected to a mini-vacuum
pump. Stimulation of saliva production was achieved by swabbing the
lateral surfaces of the tongue with 0.1 M (≈2%, w/v) citric acid every
30 s. PS was collected for 5 min and SS for 3 min. Salivary ﬂow ratewas calculated by dividing the total volume of saliva obtained by the
length of time taken to collect it and expressing the result as mL/min.
Saliva samples were divided into 100 μL aliquots and stored at−80 °C
until analyzed.
2.3. Immunoblot analysis
Salivary statherin levels were determined using a previously
described method with some modiﬁcation [6,30]. Saliva (PS and SS)
samples were thawed and ethylenediamine tetraacetic acid (EDTA)
was added to a ﬁnal concentration of 0.5 mM to minimize aggregate
formation. Following a series of pilot experiments, the volume of saliva
required to obtain an optimal statherin signal in the immunoblot analy-
sis was found to be 0.125 μL for both control and diabetic samples. Total
protein content of the saliva was determined by measuring absorbance
at 215 nmusing a DU® spectrophotometer (Beckman Coulter, CA, USA)
[26]. Bovine serum albumin was used as a standard.
Saliva samples were separated on precast 4–20% SDS-PAGE gels
(Mini-PROTEAN® TGX™, Bio-Rad Laboratories, Inc., CA, USA) and then
transferred to polyvinylidene diﬂuoride membranes (Millipore Corp,
Bedford, MA). The membranes were immunoblotted with a primary
antibody against human statherin (1:2000 dilution; STATH Polyclonal
Antibody [catalog #19724-1-AP], Proteintech, IL, USA) at 4 °C overnight,
followed by incubation with horseradish peroxidase-labeled secondary
antibody (1:10,000) (GE Healthcare Life Sciences, PA, USA). The
statherin immunoreactive band was visualized using an ECL detection
kit (ECL Advance™Western BlottingDetection Kit, GEHealthcare, Buck-
inghamshire, UK) and band imageswere acquired and analyzedwith an
AutoChemi system (UVP, Inc., CA, USA). Gray-scale values for statherin-
positive bands were quantiﬁed using Scion Image software (Scion Cor-
poration, MD, USA).
2.4. Quantiﬁcation of statherin
To compensate for variations in immunoblotting, one PS samplewas
selected from the normal controls that produced an average level of
band intensity after SDS-PAGE and immunoblotting. The integrated
gray value of this standard (0.125 μL saliva) was assigned an arbitrary
value of 100. Statherin levels in all samples were calculated relative to
this PS standard and are reported as the percent (%) statherin level for
a particular PS or SS sample.
To normalize the data, the % statherin level (calculated above) was
divided by the protein content in the saliva sample (% statherin level
divided by μg protein/μL saliva). To obtain an estimate of the rate of
statherin secretion in PS and SS, the % statherin level was multiplied
by the measured salivary ﬂow rate (mL/min).
2.5. Statistical analysis
A power analysis was performed using the statistical software,
G*Power (version 3.1.9.2) [8,9] to determine the appropriate number
of subjects to include in the study. The Mann–Whitney U-test was
used for comparing data from control and diabetic subjects. Spearman's
rank correlation coefﬁcient was used for the test of correlation between
statherin level and HbA1c and blood glucose levels. These statistical
analyses were carried out using PASW Statistics 17.0 software (SPSS,
Inc., IL, USA). A p-value less than 0.05 was considered statistically
signiﬁcant.
3. Results
The demographics of the control and diabetic subjects are shown in
Table 1. The average age of the subjects in both groups was nearly
identical and the male/female ratio was identical in each. In diabetic
subjects, median bodymass index (BMI) and HbA1c level were statisti-
cally higher when compared with controls (p = 0.049 and p b 0.001,
Table 1
Demographics of the study subjects.
Control (n = 24) Diabetics (n = 24) p value
Age (years) 67 (58.8–70.0) 67.5 (58.3–70.8) –
Gender (male/female) 11/13 11/13 –
BMI (kg/m2) 26.5 (25.0–29.3) 29 (26.3–35.8) 0.049
Fasting glucose (mg/dL) 94.5 (89.0–98.3) 199.5 (193.0–265.5) –
HbA1c (%) 5.5 (5.1–5.9) 9.0 (8.0–12.7) b0.001
Salivary ﬂow rate (mL/min)
PS 0.29 (0.11–0.43) 0.31 (0.19–0.53) 0.428 (NS)
SS 0.42 (0.30–0.51) 0.24 (0.18–0.45) 0.021
Total protein (μg/μL)
PS 1.99 (1.51–2.98) 1.88 (1.58–2.23) 0.404 (NS)
SS 1.97 (1.60–2.56) 1.52 (1.13–1.79) b0.001
The data shown are the median value for each parameter; the 25th and 75th percentile
values are shown in parentheses.
Abbreviations: PS: stimulated parotid saliva, SS: stimulated submandibular/sublingual
saliva.
p value determined using the non-parametric Mann–Whitney U-test.
–: not statistically evaluated for differences.
NS: not signiﬁcant.
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trols for the SS (p = 0.021) with no apparent changes in the PS (p =
0.428). Interestingly, the total protein concentration in SS was also
signiﬁcantly decreased (p b 0.001) in diabetics but was unchanged in
PS (p = 0.404).
Statherin was easily detected in minute amounts of saliva, using im-
munoblot analysis (Fig. 1A). The level of statherin in PSwas signiﬁcantly
decreased in diabetics as compared with controls (~45% reduction; p=
0.031; Fig. 1B); in contrast, the statherin level in SS from diabetics was
also lower, but this difference was not statistically signiﬁcant (p =
0.109; Fig. 1B). Correlation analysis revealed a negative correlation
between PS statherin levels and serum HbA1c (p = 0.012; Fig. 2A).
Similarly, a correlation was also demonstrated between PS statherin
levels and fasting glucose (p = 0.021; Fig. 2C). In contrast, there was
no signiﬁcant correlation between statherin levels and HbA1c or fasting
glucose in SS (Fig. 2B and D).Fig. 1. Statherin levels in the saliva of patientswith diabetes and healthy age- and gender-matched
submandibular saliva (SS) were collected as described in Materials and methods section and th
quantiﬁcationusing Scion Image software. Panel A: a representative gel of salivary statherin in 0.125
used for quantitation (see Materials and methods section). Panel B: statherin levels in saliva wer
density value. The relative statherin level was expressed as the ratio of statherin band density fo
1st and 3rd quartiles, median (horizontal line between the 1st and 3rd quartiles) and outliers (opWhen statherin levels were normalized to total protein in the saliva,
the proportion of statherin in PS total protein was signiﬁcantly lower in
diabetics than in healthy controls (p = 0.032; Table 2). In contrast,
the ratio of statherin to total protein in SSwas not signiﬁcantly different
between diabetics and controls. On the other hand, the amount of
statherin secretion per unit time in SS was signiﬁcantly decreased in di-
abetics compared to controls (p = 0.016), but this difference was not
observed for statherin secretion in PS (Table 2).
We also evaluated the DMFT index for the control and diabetic
subjects in this study. Both DMFT for the crown (DMFT-c) and root
(DMFT-r) are higher in diabetic patients than controls (Fig. 3). The
correlation studies showed that DMFT-r is negatively correlated
with SS salivary ﬂow rates (p = 0.026). No other correlation be-
tween DMFT-r, DMFT-c, and statherin levels was observed.
4. Discussion
We have previously shown that salivary ﬂow rates and several anti-
microbial proteins are altered innon-insulin-dependent (type2)diabet-
ic patients [6]. In the current study, we determined the level of salivary
statherin in poorly controlled type 2 diabetic patients (based on HbA1c
and fasting glucose values) compared to healthy age- and gender-
matched controls. The results show that statherin levels in diabetic pa-
tients are signiﬁcantly decreased in PS and that a negative correlation
exists between PS statherin levels and HbA1c and fasting glucose levels.
We have also shown that SS salivary ﬂow rates are reduced in diabetic
patients and diabetic patients have higher DMFT scores.
Patients with diabetes (both types 1 and 2) are known to have al-
tered salivary gland function such as decreased ﬂow rates and altered
composition [2,6,14,23,27]. In the present study, we observed that stim-
ulated SS ﬂow rates were signiﬁcantly decreased in diabetic subjects.
We did not detect any signiﬁcant decrease in stimulated PS ﬂow rates
in diabetes as indicated by some previously published studies [2]. The
reason for these discrepancies in measures of salivary function with
diabetes may be due to cohort effects, large individual variations, and
sample sizes. To the best of our knowledge, this study is the ﬁrst tocontrols asmeasured by immunoblot analysis. Stimulated parotid saliva (PS) and sublingual/
en subjected to 4–20% gradient SDS-PAGE, followed by Western blotting for statherin, and
μL saliva (PS andSS) collected fromdiabetic patients andcontrols. ST: prescreenedPS sample
e determined by converting the stained region of the immunoblot (for each sample) into a
r an individual subject to the standard PS sample run on each gel. The box plots show the
en circles) [more than 1.5× (3rd–1st quartiles)].
Fig. 2. Correlation between salivary statherin levels and fasting blood glucose and HbA1c levels in patients with diabetes and healthy age- and gender-matched controls. Normalized
statherin levels in stimulated parotid saliva (PS, panels A and C) and stimulated submandibular/sublingual saliva (SS, panels B and D) were plotted against HbA1c (panels A and B) or
fasting blood glucose (panels C and D) levels. A signiﬁcant negative correlation was found between PS statherin and HbA1c (panel A) and fasting blood glucose (panel C).
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betics. Previously, a quantitative peptidomic study of whole saliva sug-
gested a decrease in salivary statherin levels of type 1 diabetic patients
[1]. A lower immunoreactive statherin level in parotid, submandibular
and labial glands from diabetic patients has also been reported using
an immunogold transmission electron microscopy approach [11,12].
The effect of diabetes on statherin secretion appears to be more pro-
nounced on PS than SS as statistically signiﬁcant differences were only
observed in PS (see Table 2, % statherin levels and % statherin levels nor-
malized to protein). Since no differences in PS ﬂow rate and total pro-
tein concentrations were found between healthy controls and
diabetics (Table 1), statherin levels in PS appear to be directly inﬂu-
enced by the hyperglycemia of diabetes mellitus. This conclusion is fur-
ther supported by our results showing a negative correlation betweenTable 2
Salivary statherin in diabetic and control subjects.
Statherin level
(% statherin)
Statherin lev
(% statherin
PS Control subjects 97.0
(59.5–127.0) (2
Diabetic subjects 53.0⁎
(26.5–119.0) (1
SS Control subjects 25.5
(13.8–57.5) (
Diabetic subjects 13.0
(4.0–44.0) (
The data shown are the median value for each parameter; the 25th and 75th percentile values
The % statherin level in a 0.125 μL aliquot of saliva was calculated in relation to the amountmea
section. These datawere then normalized to the total protein content in a μL saliva (=% statherin
level/total protein in a μL saliva by salivary ﬂow rate (mL/min).
Abbreviations: PS: stimulated parotid saliva, SS: stimulated submandibular/sublingual saliva.
⁎ p b 0.05 vs. control subjects.PS statherin levels and HbA1c and fasting glucose levels (see Fig. 2).
However, prior studies have reported that immunoreactive statherin
is only present in serous acinar cells. The less pronounced effect of dia-
betes on statherin levels in SS may be due to differences in the acini of
these two glands. In addition, in the present study, the effect of diabetes
on statherin production by individual submandibular and sublingual
glands could not be evaluated as we did not collect separate saliva sam-
ples from these two glands [28].
Our results further demonstrate that SS ﬂow rate and total protein
concentrations are signiﬁcantly lower in diabetic patients. Prior studies
have shown that statherin concentrations increase with salivary ﬂow
rates [16]. The decrease in median statherin levels in SS of diabetic pa-
tients, although not signiﬁcant, may relate to the signiﬁcantly reduced
salivary ﬂow rates found in diabetes (see Fig. 1). Currently, the cellularel normalized to protein
/ μg protein/μL saliva)
Total statherin secretion
(% statherin / μg protein/μL saliva) × (mL/min)
43.19
9.67–63.12)
22.97
(15.38–33.28)
26.26⁎
3.51–53.17)
15.37
(6.93–27.50)
14.06
6.34–25.46)
11.41
(5.21–21.88)
8.55
4.00–31.66)
3.38⁎
(1.25–12.69)
are shown in parentheses.
sured in a pre-screened PS sample of equal volume as described inMaterials andmethods
level/total protein). Total statherin secretionwas calculated bymultiplying the% statherin
Fig. 3.Decayed,missing and ﬁlled teeth (DMFT) index for tooth crown (DMFT-c) or dental
root (DMFT-r) in patients with diabetes and healthy age- and gender-matched controls.
The box plots represent the 1st and 3rd quartiles, median (horizontal line between the
1st and 3rd quartiles) and outliers (open circles) [more than 1.5× (3rd–1st quartiles)].
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function in diabetes, are unclear. Morphological, immunolabeling and
functional studies of salivary glands, using experimental animal models
and clinical samples, indicate that diabetes leads to changes in the auto-
nomic nervous system [22,31], lower expression of cyclic AMP receptors
and secretory proteins (e.g., amylase, proline-rich proteins, andmucins)
[21,24], and structural changes in cellular organelles (e.g., increased
acinar and secretory granule area, reduced mitochrondria size, and
increased membrane folding) [19,31] as compared to normal salivary
gland cells. Whether these alterations contribute to, or are associated
with, differences in salivary statherin levels between diabetes and
healthy controls require further study. Nevertheless, statherin, an abun-
dant salivary protein as our results demonstrate, can serve as a marker
for studying the effect of diabetes on salivary function.
Statherin is a major salivary protein with multiple physiological
functions. Reduced statherin levels in PS and total statherin secretion
in SS can put diabetic patients at risk for a number of oral diseases.
Indeed, statherin levels have been associated with elevated decayed,
missing, andﬁlled teeth/surfaces (DMFT/DMFS) indices [29].While a di-
rect correlation between statherin levels and DMFTs were not found in
the current study, theDMFT index for crown and rootswere both higher
in diabetic patients compared to the healthy non-diabetic controls and
conﬁrmed previous studies demonstrating an association between dia-
betes andDMFT [15,17]. Thus far, the association of dental caries and di-
abetes has not beenwell documented [17]. In contrast, diabetic patients
are known to be at a higher risk for more severe periodontal diseases
[17]. The lower salivary ﬂow rates and periodontal diseases among dia-
betic patients may partially explain the higher DMFT-c and DMFT-r in
diabetic patients [10,17]. In our cohort, the differences in DMFTs may
derive from missing teeth since the diabetic group has signiﬁcantly
more missing teeth (data not shown). Whether the missing teeth are
due to periodontal disease or caries is currently unclear. Regardless,
the lower statherin concentration and secretions in this study suggest
a potential major risk for oral diseases in diabetic patients.
In prior studies, salivary statherin levels have been quantiﬁed with
chromatography, ELISA and immunodiffusion assays using investigator
prepared statherin or its antibodies [4,16,18]. In this study, we devel-
oped a highly sensitive method for speciﬁcally quantifying statherin insaliva using gel electrophoresis and immunoblottingwith commercially
available antibodies. The immunoblot analysis allowed the relative
quantiﬁcation of statherin with b0.5 μg total salivary protein
(~0.125 μL saliva). The primary antibody used in this study does
not cross-react with rodent saliva or salivary gland tissue as predict-
ed by phylogenetic studies [5]. The commercially available antibod-
ies open the way for developing highly sensitive antibody-based
assays for measuring statherin and exploring the role of statherin
in the pathogenesis of oral diseases.
In conclusion, we have shown that statherin levels in PS and the
statherin secretion rate in SS are decreased in poorly controlled diabetic
patients compared to non-diabetic controls. In addition, statherin levels
in PS were negatively correlated with blood glucose and HbA1c levels.
We have further demonstrated that diabetic patients have a higher
DMFT index and lower salivary ﬂow rates. Alterations in statherin
level and secretion, in combination with compromised salivary ﬂow
rates, may account for the higher incidence of oral complications in di-
abetic patients. Oral diseases, especially periodontal diseases have
been linked to diabetic control, further emphasizing that oral health
maintenance should be an integral part of diabetic management [17].Transparency document
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